Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.
暂无分享,去创建一个
Julie A Johnson | Michael Conlon | Amanda R Elsey | Michael J Clare-Salzler | David Nessl | David R Nelson | Julie A. Johnson | D. Nelson | M. Conlon | A. Elsey | David Nessl | M. Clare-Salzler | Amanda Elsey
[1] K. Sangkuhl,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy , 2011, Clinical pharmacology and therapeutics.
[2] M. Whirl‐Carrillo,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing , 2011, Clinical pharmacology and therapeutics.
[3] R. Altman,et al. Implementing Personalized Medicine: Development of a Cost‐Effective Customized Pharmacogenetics Genotyping Array , 2012, Clinical pharmacology and therapeutics.
[4] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype , 2012, Clinical pharmacology and therapeutics.
[5] T E Klein,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing , 2011, Clinical pharmacology and therapy.